Simian virus 40 vectors for pulmonary gene therapy by Eid, Luminita et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Respiratory Research
Open Access Research
Simian virus 40 vectors for pulmonary gene therapy
Luminita Eid1, Zohar Bromberg2, Mahmoud Abd EL-Latif3, Evelyn Zeira2, 
Ariella Oppenheim3 and Yoram G Weiss*1,4
Address: 1Department of Anesthesiology and Critical Care Medicine, Hadassah – Hebrew University Medical Center, Jerusalem, 91120, Israel, 2The 
Goldyne Savad Gene Therapy Institute, Jerusalem, 91120, Israel, 3Department of Hematology, Hadassah – Hebrew University Medical Center, 
91120, Jerusalem, Israel and 4Department of Anesthesiology and Critical Care, University of Pennsylvania School of Medicine, Philadelphia, PA 
19104-4283, USA
Email: Luminita Eid - luminita25@yahoo.com; Zohar Bromberg - zoharb@hadassah.org.il; Mahmoud Abd EL-Latif - msa97@hotmail.com; 
Evelyn Zeira - evezeira@hadassah.org.il; Ariella Oppenheim - ariella@cc.huji.ac.il; Yoram G Weiss* - weiss@hadassah.org.il
* Corresponding author    
Abstract
Background: Sepsis remains the leading cause of death in critically ill patients. One of the primary
organs affected by sepsis is the lung, presenting as the Acute Respiratory Distress Syndrome
(ARDS). Organ damage in sepsis involves an alteration in gene expression, making gene transfer a
potential therapeutic modality. This work examines the feasibility of applying simian virus 40 (SV40)
vectors for pulmonary gene therapy.
Methods: Sepsis-induced ARDS was established by cecal ligation double puncture (2CLP). SV40
vectors carrying the luciferase reporter gene (SV/luc)  were administered intratracheally
immediately after sepsis induction. Sham operated (SO) as well as 2CLP rats given intratracheal PBS
or adenovirus expressing luciferase served as controls. Luc transduction was evaluated by in vivo
light detection, immunoassay and luciferase mRNA detection by RT-PCR in tissue harvested from
septic rats. Vector abundance and distribution into alveolar cells was evaluated using
immunostaining for the SV40 VP1 capsid protein as well as by double staining for VP1 and for the
surfactant protein C (proSP-C). Immunostaining for T-lymphocytes was used to evaluate the
cellular immune response induced by the vector.
Results: Luc expression measured by in vivo light detection correlated with immunoassay from
lung tissue harvested from the same rats. Moreover, our results showed vector presence in type
II alveolar cells. The vector did not induce significant cellular immune response.
Conclusion: In the present study we have demonstrated efficient uptake and expression of an
SV40 vector in the lungs of animals with sepsis-induced ARDS. These vectors appear to be capable
of in vivo transduction of alveolar type II cells and may thus become a future therapeutic tool.
Background
Sepsis is the leading cause of death in critically ill patients
[1]. Despite advances in treating the sepsis syndrome, the
incidence and mortality of sepsis remains high (35–45%)
[2]. Lung is the organ most often involved, with lung
injury taking the form of Acute Respiratory Distress Syn-
drome (ARDS) [3-5], carrying 40% mortality [6]. The
pathological hallmark of ARDS is airspace flooding with
Published: 29 October 2007
Respiratory Research 2007, 8:74 doi:10.1186/1465-9921-8-74
Received: 28 March 2007
Accepted: 29 October 2007
This article is available from: http://respiratory-research.com/content/8/1/74
© 2007 Eid et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2007, 8:74 http://respiratory-research.com/content/8/1/74
Page 2 of 11
(page number not for citation purposes)
proteinaceous fluid, basement membrane disruption,
hyaline membrane deposition, surfactant depletion,
interstitial swelling, and interstitial neutrophilic infiltra-
tion [7]. Histological sections of the lungs from patients
dying of ARDS and from animal models of the disease
reveal: interstitial edema, followed by extensive necrosis
of alveolar epithelial cells [8].
Alveolar epithelium in the adult lung consists of two cell
types: Type I, differentiated cells that facilitate gas
exchange and Type II, metabolically active cells involved
in surfactant secretion and epithelial repair, serving as
progenitors for injured type I cells [9]. Injury to type II
cells impairs gas exchange by reducing the surfactant sup-
ply and limits type I cells regeneration, their preservation
being essential for recovery from ARDS [10].
Nowadays therapy for ARDS remains mainly supportive,
designed to prevent secondary injury [11]. However,
recent studies demonstrated that organ damage in sepsis
involves an alteration in gene expression. Decreased tran-
scription of surfactant proteins [12] as well as profound
pulmonary epithelial dysregulation together with altered
levels of Hsp70 were found in animal models of ARDS
[13]. We also showed in our previous studies that severe
sepsis induced by cecal ligation and puncture (2CLP) pre-
cipitates ARDS [13,14]. Furthermore, we demonstrated
that enhanced Hsp70 expression in pneumocytes using an
adenoviral vector (AdHSP) not only decreased histologi-
cal abnormalities in the lung but also improved short-
term outcome [15]. Specifically, we showed that AdHSP
limited sepsis-induced acute inflammation by suppress-
ing NF-κB activation [50].
One approach to correct deficient protein expression is to
use viral mediated gene transfer [16]. An optimal vector
for gene therapy should be safe, efficient, nonimmuno-
genic, and available in high titers [17]. There is currently
no single vector with all these advantages. SV40 based vec-
tors are efficient gene delivery vehicles for a wide spectrum
of ex vivo and in vivo targets, including hematopoetic, liver
and kidney cells [18,19]. The vector was shown to be
potentially effective in a number of clinical models,
including Crigler Najjar syndrome [20], HIV, [21] cancer
immunotherapy, [22-25], liver cirrhosis [26].
SV40 evades host immune response most likely by caveo-
lar endocytosis, followed by vesicular transport to the
endoplasmic reticulum [27], thus avoiding the more com-
mon endosomal-lysosomal pathway used by most viruses
[28]. SV40 vectors were found to be nonimmunogenic,
allowing repeated administrations and long survival of
transduced cells [29,30]. Replication incompetent SV40
vectors in which the viral T-antigen is replaced by the gene
of interest are produced in vivo in cells that supply T-anti-
gen in trans-, such as COS or COT cells [31], and high vec-
tor titers may be readily prepared [32]. Cloning capacity of
these vectors is limited; nevertheless, many potentially
therapeutic genes may be accommodated, as shown by
the wide spectrum of applications already investigated.
The use of SV40 vectors for gene transfer to the lung has
not been explored. In this work we found that SV40 vec-
tors may be used for lung cell transduction. After in vivo
vector delivery, we established and measured expression
of the reporter gene in rats with sepsis induced ARDS. Our
results lead the way for studies regarding gene delivery to
the lung, in order to modulate pulmonary disease proc-
esses.
Methods
Vector Construction
SV/luc is a T-antigen replacement vector carrying the firefly
luciferase (luc) reporter gene [33]. Preparation of the SV/
luc  vector was performed as previously described [34].
Recombinant E1, E3-deleted adenoviral vectors (Ad/luc)
were propagated in HEK293T cells, by commonly used
methods[35].
Induction of Sepsis/ARDS and Vector Administration to 
Rats
Animal procedures were approved by the Institutional
Animal Care Ethical Committee. Under Ketamine/Xyla-
sine/Isoflurane anesthesia, severe sepsis was induced in
Sprague-Dawley rats using cecal ligation double puncture
(2CLP) [14]. 1.25 × 108 IU/ml (infectious units) of SV/luc
in 300 μl PBS were administered via a tracheal catheter to
2CLP and sham operated (SO) rats immediately after the
procedure and to unoperated (UO) rats. In the positive
control group, 109 IU/Ad/luc in 300 μl PBS were adminis-
tered in the same way to 2CLP animals [15]. Negative con-
trol animals received PBS only.
In vivo Light Detection
The reporter gene used encodes the luciferase protein, an
enzyme that converts luciferin in presence of oxygen and
ATP to a bioluminescent substance. In vivo light detection
was performed using the Roper Chemiluminescence
Imaging System, (CCCD-cooled coupled charged camera)
model LN/CCD-1300EB equipped with ST-133 controller
and a 50 mm Nikon lens (Roper Scientific, Princeton
Instrument, Trenton, NJ). The system enables detection of
an internal light signal emerging from mammalian tissue.
The measurement is the sum of the integrated light signal
subtracted the background light emission of an area of
equal size [36]. A pseudo color image represents light
intensity spectrum (from blue – least intense, to red –
most intense).Respiratory Research 2007, 8:74 http://respiratory-research.com/content/8/1/74
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Forty eight hours after vector administration, rats were
reanesthetized. 125 mg/kg Beetle Luciferin (Promega,
Madison, WI) was administered intraperitoneally, and
luciferase activity was measured by photographing the
animals first in light (to obtain the animal's image) and
then in the dark (to measure light emission). A composite
photograph was obtained by superimposing the two
images. The average amount of fluorescence measured in
light units per area, as detected by the CCCD camera rep-
resents signal intensity.
Tissue Preparation
After the light emission measurement, at 48 hrs, the ani-
mals were sacrificed and internal organs harvested. One
lung was removed, preserved in formalin, embedded in
paraffin, cut at 5 μm thickness and stained with hematox-
ylin and eosin. H&E sections were evaluated for lung
injury, degree of injury and its distribution within the
lungs [14]. Part of the spleen, liver, heart and one kidney
were also harvested and prepared in the same way. The
remaining part of the spleen, heart, liver, the second kid-
ney and lung were frozen in fluid nitrogen and preserved
at -80°C for RNA.
Immunohistochemical Detection
Immunostaining was performed using the procedure
described by Lavon et al [37]. For luciferase we used a pri-
mary rabbit anti-mouse polyclonal antibody (Cortex, San
Leandro, CA) at 1:50 dilution, followed by a secondary
goat anti-rabbit IgG antibody (biotin conjugated, Zymed,
San Francisco, CA). VP1 capsid protein detection was per-
formed using a rabbit anti-SV40 polyclonal primary
antiserum [38] followed by FITC-conjugated goat anti-
rabbit IgG secondary antiserum (Zymed). DAPI (blue)
was used as nuclear counterstain. Double immunostain-
ing for surfactant protein C (ProSP-C) and VP1 was per-
formed in order to detect internalization of VP1 viral
capsid protein into the alveolar cells. Serial lung sections
were immunostained for VP1 using the same rabbit poly-
clonal antibody as above followed by goat anti-rabbit
Cyte 5, and for ProSP-C using rabbit anti-ProSP-C poly-
clonal primary antiserum (Alomone Inc, Israel) followed
by FITC-conjugated goat anti-mouse IgG. Immunohisto-
chemical detection of Lymphocyte (CD3+ T cells) infiltra-
tion was performed using the immunoperoxidase avidin
biotin methodology. A primary CD3+ T cell antibody
(monoclonal mouse anti-rabbit, affinity purified, Bio-
source, Carlsbad, California) at 1:100 dilution was used,
followed by a secondary goat anti-rabbit IgG antibody
(biotin conjugated, Zymed).
Reverse Transcription – RT-PCR
Total RNAs from the frozen tissues were extracted using
Trireagent (Sigma, Saint Louis, MO) according to the
manufacture's instructions. A quantity of 2.5 μg of
extracted RNA (for each sample) was subjected to reverse
transcription using 400 u/μl RNAse, 0.5 μg/μl oligo dT,
200 u/μl M-MLV RT and 2.5 mM dNTPs. 2 μl of the react-
ing cDNA products were used as template for PCR. PCR
was performed using PCR primers specific for Luciferase:
5'-TGGTCTGCCTAAAGGTGTCG-3' (forward) and 5'-
ATGTAGTCTCAGTGAGCCC-3' (reverse), and carried out
for 35 cycles. pGL3 Luciferase reporter vector (Promega)
served as a positive control. GAPDH was used as a house
keeping control gene, using PCR primers specific for
GAPDH: 5'-ACCACAGTCCATGCCATCAC-3' and 5'-
TCCACCACCCTGTTGCTGTA-3'.
Results and Discussion
Sepsis induces ARDS
In the present experiment, ARDS was induced secondary
to intra-abdominal sepsis (2CLP). Starting 12 hours after
2CLP, and more prominently at 24 and 48 hours, 2CLP
rats displayed the typical signs of sepsis: intense pallor/
cyanosis of the mucous membranes, dirty fur with erected
hairs, distended abdomen, diarrhea, tachypnea (40–60
breath per minute). Animal behavior was grossly abnor-
mal: periods of agitation followed by periods of sleepiness
along with limited movements and inability to feed.
Histological examination of the lung sections from 2CLP
animals showed changes consistent with ARDS. Macro-
scopically: lungs were less aerated, covered with white
fibrin patches and pleural fluid was found in different
quantities. H&E stained sections depicted: alveoli filled
with proteinaceous fluid, septal thickening, and intersti-
tial neutrophilic infiltration (Figure 1). Mortality was
present only in the septic (2CLP) animals. The 48 hrs
mortality rate following 2CLP was similar to previously
published numbers in sepsis induced ARDS [13-15].
Use of SV40 vectors in ARDS
SV/luc or Ad/luc vectors were directly administered into
the trachea of 2CLP and SO rats, immediately following
the procedure. Using this route we achieved maximal vec-
tor concentration and distribution to the lung, limiting
the systemic spread. Histopathologically there was no dif-
ference between the lungs of the septic rats given PBS or
SV/luc (Figure 1). Mortality rate was similar in 2CLP ani-
mals given either PBS or SV/luc, suggesting that the vector
itself did not add to the sepsis/ARDS induced mortality.
Sepsis-induced ARDS increases Luciferase expression
At 24 and 48 hours, all the animals were reanesthetized
and photographed with the CCCD camera to detect light
emission. At 48 hours all animals were sacrificed and the
lungs were harvested.
At 24 hours, Luciferase activity was not detected in any
animal groups. We explain this finding by the timeRespiratory Research 2007, 8:74 http://respiratory-research.com/content/8/1/74
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needed for the reporter gene to express. However, at 48
hours, luc activity (detected as luminescence by the CCCD
camera) was seen over the lung areas in 2CLP animals
given SV/luc (Figure 2a). Low levels of luc activity were
detected in the tracheostomy region, confirming a degree
of vector affinity for airway epithelium (Figure 2b). No luc
activity was detected in rats given PBS. No significant in
vivo luc activity was detected in the heart, liver, spleen or
kidneys of the animals given SV/luc.
Fluorescence over the lungs of SO rats was significantly
lower than that seen in 2CLP animals (Figure 2a). Intrat-
racheal administration results in little vector uptake in the
normal lungs of SO rats, while changes in the intracellular
structure occurring during ARDS may be responsible for
enhanced viral expression. Similar findings were observed
with adenoviruses, and explained by an ARDS-induced
exposure/expression of the CAR and integrin receptors
that mediate adenoviral entry into the alveolar cells [14].
This mechanism may also apply to the SV40 vector,
although different receptors or increased endocytosis may
be involved. [39-41].
Based on our previous findings [14,15], a comparison of
luc activity between SV/luc and Ad/luc vectors was per-
formed. As expected, luc expression was lower in the
2CLP-SV/luc than in the 2CLP-Ad/luc group (Figure 2c,
2d), because of the natural tropism of adenoviral vectors
for the pulmonary epithelium [14]. Another factor may
have been the higher titer of the adenoviruses used, a total
of 109 IU/ml adenoviral vector as compared to 1,25 × 108
IU/ml of the SV40 vector.
Positive luciferase immunostaining in ARDS lung
Luc immunostaining was nonspecific, involving both
alveolar type I type II cells. It was moderate in septic ani-
mals and low in SO animals (Figure 3). This may be due
to moderate infectivity of the SV40 vector in the lungs or
weak activity of the SV40 promoter in alveolar cells. This
finding is also consistent with the literature, describing
less transgene expression of some non – mammalian, non
– vertebrate encoded proteins (e.g. luciferase, GFP, lac Z)
commonly used as markers for transduction in SV40 vec-
tors, than is usually seen with other vector systems (e.g.,
adenovirus) [18].
Immunostaining for luciferase in the liver, kidney, spleen
and the heart was negative in both 2CLP and SO animals
groups given SV/luc, suggesting that direct intratracheal
administration of the vector results in negligible systemic
spread despite alterations in membrane permeability and
capillary leak seen in ARDS.
Positive VP1 immunostaining in ARDS lungs
In order to test if the low level of Luc immunostaining in
lung tissue is due to a low vector penetration into the alve-
olar epithelium or to low expression of the reporter gene,
we tested for the presence of the VP1 capsid protein by flu-
orescent immunostaining. A significantly higher number
of alveolar cells contained viral capsid proteins compared
with the number of luc positive cells (Figure 4a, 4b, and
Lung pathology Figure 1
Lung pathology. H&E stained lung tissue, shown at ×20 and ×100 magnifications. Untreated control rats show normal lung 
histology; SO rats given intratracheal SV/luc also show normal histological appearance; 2CLP rats given intratracheal PBS or SV/
luc show distinct ARDS pathology: alveoli filled with proteinaceous fluid, septal thickening, interstitial lymphocytic and neu-
trophilic infiltration.Respiratory Research 2007, 8:74 http://respiratory-research.com/content/8/1/74
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compare with Figure 3). This suggests that vector penetra-
tion into lung epithelial cells is efficient, but transgene
expression in many of the cells is below detection level. It
is possible that the SV40 promoter used in the present vec-
tor is weak and therefore gene expression is lower than
gene delivery. A stronger, lung specific promoter may sig-
nificantly improve expression of a therapeutic gene in
alveolar cells.
The vector infects alveolar type II cells
Alveolar type II cells participate in the regenerative process
of the lung. Therefore their transduction is critical for suc-
cessful ARDS gene therapy.
To examine this we performed co-immunostaining of
lung tissue for surfactant protein C (Pro SP-C) a marker
for alveolar type II cells and VP1 viral capsid protein (Fig-
ure 5). The figure depicts co-localization of Pro SP-C and
VP1. These findings support our conclusion that the vec-
tor is internalized into alveolar type II cells. The ability to
transduce these cells is essential because of their impor-
In vivo detection of luminescence Figure 2
In vivo detection of luminescence. Detection was performed with a CCCD camera (exposure time 2 min) 48 hours fol-
lowing intratracheal administration of 300 μl of 1.25 × 108 IU/ml SV/luc. 2a: A typical 2CLP rat showing luc activity over right 
lung and tracheostomy areas (right), left lung and tracheostomy areas (middle), and SO rat showing very low luc activity over 
pulmonary area (left). The color scales values are indicated on the wedge.2b: Graphic representation of means and standard 
deviations of 2CLP + SV/luc treated rats. Rt – right lung, Lt – left lung, Trach – tracheostomy area. The values represent the 
mean for 8 animals and the bars represent standard deviations. The signal over the lung area was different from the signal of 
tracheal area at P < 0.03 for both left and right lungs.2c: Comparison of SV/luc and Ad/luc transduction (exposure time 2 min) 
at 48 hours in a rat given intratracheal 300 μl of 1.25 × 108IU/ml SV/luc (left) and a rat given intratracheal 300 μl of 1 × 109 IU/
ml Ad/luc (right).2d: Graphic representation of means and standard deviations of 2CLP + SV/luc (8 treated rats, black bar) and 
2CLP+Ad/luc (3 treated rats, gray bar).Respiratory Research 2007, 8:74 http://respiratory-research.com/content/8/1/74
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tance in alveolar epithelial repair processes and lung
recovery in ARDS [10].
Luciferase mRNA detection
RT-PCR was performed on frozen tissues of the lung, kid-
ney, liver, spleen and heart. High levels of mRNA were
detected in the lungs of 2CLP animals, similar to those
found in the plasmid pGL3 used as positive control for
luciferase. Minimal levels were present in the liver, kidney
spleen and none at all in the heart, confirming minimal
systemic spread of the vector after direct intratracheal
instillation. Interestingly, in T0 and SO controls, minimal
Detection of the VP1 capsid protein in lung tissue Figure 4
Detection of the VP1 capsid protein in lung tissue. 4a: Positive staining for VP1 protein appears as red intracytoplas-
matic coloration: moderate for SO rats (above) and high for 2CLP rats (below). DAPI (blue) was used as nuclear counter-stain. 
4b: Negative control for VP1 immunostaining. Above: lung tissue from control septic rats given intratracheal PBS, and below: 
normal lung tissue from a control T0 rats. The minimal staining seen represents the background. DAPI (blue) was used as 
nuclear counter-stain. Shown at ×40 magnification.
Luciferase immunostaining Figure 3
Luciferase immunostaining. Was performed on the lung tissue harvested from 2CLP and SO rats given intratracheal SV/luc. 
Positive immunostaining appears as brown intracytoplasmatic coloration (Black arrows). Shown at ×100 magnification.Respiratory Research 2007, 8:74 http://respiratory-research.com/content/8/1/74
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expression was noticed in the lungs, in spite of the same
route of vector administration, suggesting that the patho-
logical processes taking place in the sepsis-induced ARDS
lungs (as in 2CLP animals) enhances vector penetration
and expression by an unknown mechanism. Regarding
the kidney, liver, spleen and heart of T0 and SO animals,
the same minimal expression was observed as in the septic
animals (Figure 6).
Cellular immune response to SV40 vectors
Direct intratracheal administration of SV/luc induced no
immunological response as measured by lymphocytic and
neutrophilic infiltration of the H&E stained lung sections
compared to PBS treated septic lung (Figure 1). To further
confirm this we performed immunohistochemical detec-
tion for lymphocytic (CD3+ T cells) infiltration (Figure
7a, 7b). As expected, inflammatory cell infiltration was
higher in the ARDS compared to the SO lungs. However
lymphocytic infiltration in the SV/luc and PBS treated sep-
tic rats was similar, indicating that the SV40 vector does
not elicite an excessive cellular immune response. These
findings support our previous results which demonstrated
that there was no cellular immune response against the
vector or the transgene following liver transduction by the
SV/luc vector, measured by lymphocyte proliferation assay
at 84–110 days following vector administration [30].
Moreover, literature data reported that neutralizing anti-
body activity against an SV40 vector was not detected in
the serum of treated mice, even after 8 consecutive intra-
peritoneal or subcutaneous inoculations [29]. In our pre-
vious study we detected marginal humoral immune
response against the vector only at very high vector con-
centration [30]. Two factors appear responsible of this
behavior: the uncommon cell entry route (SV40 vectors
evade immune surveillance most likely by entering cells
via caveolar endocytosis, followed by vesicular transport
directly into the endoplasmic reticulum, bypassing the
endosomal-lysosomal pathway) [27], and deletion of T
antigen of the viral genome (renders the vector nonimmu-
nogenic) [32].
Conclusion
The results presented in this article are only preliminary
data. Currently, the most common vectors for gene trans-
fer to the lung are replication-deficient adenoviruses. The
major advantage of adenovectors is their excellent effi-
ciency in gene transfer. However, gene expression is tran-
sient and the immunogenicity prevents repeated
administrations. Moreover, the preparation of a gutless
adenovirus with a more extended expression is technically
demanding [42].
VP1 detection in type II cells Figure 5
VP1 detection in type II cells. The cells were double-stained for VP1 and Pro-SP C as described in Materials and Methods. 
An SO lung is shown at the top row and ARDS lung in the bottom row. VP1 was detected by Cyte5 (red fluorescence, left pan-
els) and Pro-SP C by FITC (green fluorescence, middle panels). The upper and lower right images show co-localization of both 
stainings inside alveolar type II cells (yellow). Shown at ×100 magnificationRespiratory Research 2007, 8:74 http://respiratory-research.com/content/8/1/74
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After a detailed search of the literature data we can con-
firm that this is the first experiment in which an SV40
based vector was used for transduction of lung cells. The
goal of our research was to provide a basis for the use of
these vectors in face of their advantages over adenoviral
vectors, as well as their limitations.
In spite of the two major barriers met by the viruses after
intratracheal administration: the mucociliary clearance
system and the glycocalix [42], in the present study we
have demonstrated efficient uptake of an SV40 vector in
the lungs of animals with sepsis-induced ARDS. Although
nonspecific, these vectors appear to be capable of in vivo
transduction of alveolar type II cells, key cells involved in
regenerative process of the lung [10].
Acute respiratory disorders like ARDS are the result of a
variety of endogenous and exogenous influences, arising
rather as a misbalance between protective and destructive
mechanisms. Transient gene therapy may thus help
restore the homeostatic balance by short term expression
of protective genes or suppression of damaging genes
[43]. In the near future we plan taking this research a step
further by replacing the reporter gene with a therapeutical
one (encoding one of the surfactant proteins, Hsp70 or
interleukin 6) and trying to alter the course of the disease.
SV40 vectors are generally considered non-integrating,
transiently expressing vectors [44]. Although others
reported a prolonged expression of rSV40 vectors (1
month -1 year) [30], we did not estimate the duration of
transgene expression, as our study was limited to 48
hours. Short term or transient gene expression may be suf-
ficient and even advantageous for the treatment of an
acute condition like ARDS, where a therapeutic protein or
enzyme may be only needed during the acute state. How-
ever, as these vectors elicit marginal immune response,
repeated administrations, if required, would be possible.
Our results show moderate expression of the luciferase
reporter gene. Use of a CMV promoter in the construction
of the SV40 vector may improve transgene expression.
However, low level of proteins expression may not be
entirely disadvantageous. Supra-physiological production
of specific proteins may lead to unexpected side effects. In
contrast, low expression may be augmented by repeated
administrations of the vector [40]. With the SV40 vector
RT-PCR for luciferase mRNA detection Figure 6
RT-PCR for luciferase mRNA detection: High levels of mRNA were detected in the lungs of 2CLP animals (plasmid pGL3 
used as positive control for luciferase). Minimal levels were present in the liver, kidney spleen and none in the heart. Minimal 
expression in the lungs, kidney, liver, spleen, and heart of T0 and SO animals. GAPDH was used as a house keeping control 
gene, using PCR primers specific for GAPDH.Respiratory Research 2007, 8:74 http://respiratory-research.com/content/8/1/74
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repeated administrations are possible due to its low
immunogenicity.
Safety considerations require that the vectors do not con-
tain replication associated T antigen sequences. For this
reason our vector is T antigen deleted. Vector propagation
is achieved in COT18 cells, cell lines with minimal
sequence identity with the vector. Reacquisition by rSV40
of T antigen DNA and reemergence of wtSV40 virions
remains extremely unlikely [30].
Another major advantage with SV40 vectors is that they
may be constructed in vitro by packaging DNA of choice in
recombinant capsids [45]. These vectors, which combine
efficient gene delivery of viral vectors with safety and flex-
ibility of non-viral vectors, were shown to have similar
tropism as standard SV40 vectors such as the SV/luc
described here [30]. Furthermore, these vectors accommo-
date plasmids as large as 17 kb, significantly larger than
SV40 DNA, and may be therefore used to deliver a variety
of genes with complex regulatory signals [46]. Further-
more, these vectors do not require any SV40 sequences,
providing additional safety margin [47-49].
The present study suggests that in vitro constructed SV40
vectors may be tailored to deliver genes of choice with
lung-specific promoters for treatment of acute respiratory
diseases like ARDS.
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